stock & financial message boards
  Joined Today: 2

  Login  |  Registration |  Site Map  |  Stock Market Blogs reaching thousands of users every day  |  Recent Activity  |    |

« Previous | Next » | All Messages |  OSCI Message Board Home | recommend post |  Ignore Poster

Message #57
From: FastFun
Date: October 20, 2007 10:31:43 PM

Webcast Alert: Oscient Pharmaceuticals Announces Date for Release of Third Quarter Financial Results

 

Oscient Pharmaceuticals Corporation (Nasdaq:OSCI) will release financial results for the third quarter ended September 30, 2007 on Wednesday, October 31, 2007 prior to the opening of the U.S. financial markets. A conference call will be held at 8:30 a.m. Eastern Time with Steven Rauscher, President and CEO, and other members of Oscient’s management team. The Company announced preliminary revenue results for the third quarter on October 10, 2007.

What: Third Quarter Financial Results

When: October 31, 2007 at 8:30 am Eastern Time

How: Domestic participants can access the call by dialing 1-888-634-4009. International participants are asked to dial 1-706-634-2285. The call will also be webcast through the Company’s website at www.oscient.com.

A replay will be available two hours after the conclusion of the call until November 7, 2007. Domestic participants can access the replay by dialing 1-800-642-1687, while international participants are asked to dial 1-706-645-9291. The conference ID number for the replay is 21006225. A replay will also be available through www.oscient.com.

About Oscient Pharmaceuticals

Oscient Pharmaceuticals Corporation is a commercial-stage pharmaceutical company marketing two FDA-approved products with its national primary care sales force. ANTARA® (fenofibrate) capsules is indicated for the adjunct treatment of hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE® (gemifloxacin mesylate) tablets is an antibiotic approved for the treatment of acute bacterial exacerbations of chronic bronchitis and community-acquired pneumonia of mild to moderate severity. Oscient also has a novel, late-stage antibiotic candidate, Ramoplanin, under investigation for the treatment of Clostridium difficile-associated disease (CDAD).

For important information regarding the safety and use of ANTARA and FACTIVE, please see the full prescribing information available at www.antararx.com and www.factive.com.

Oscient Pharmaceuticals Corporation
Christopher Taylor, 781-398-2466
or
Sarah Emond, 781-398-2544


Source: Business Wire (October 18, 2007 - 4:03 PM EDT)

News by QuoteMedia
www.quotemedia.com

« Previous | Next » | All Messages |  OSCI Message Board Home | Ignore Poster